Medication info

Trapholmin Duo Extended-Release Tablet 2.5/750 mg

Prescription medicationTabletOral
Ingredient · strength
Linagliptin Micronized›2.5mg / 1 tabletMetformin Hydrochloride with Colloidal Anhydrous Silica›757.5mg / 1 tablet
Manufacturer / importer
Daewon Biotech Co., Ltd.
Appearance
Light pink, convex on both sides, oval-shaped extended-release film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202400630 · Approved 2024.03.25

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
In antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5 mg and metformin hydrochloride extended-release 2000 mg. This drug should be taken once daily with a meal, preferably with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. To maintain the extended-release properties, swallow this drug whole; do not split, crush, grind, or chew it. Take 1 tablet of this drug 5/1000 mg extended-release tablet once daily. Patients taking this drug 2.5/750 mg extended-release tablet or 2.5/1000 mg extended-release tablet should take 2 tablets together once daily. 1. If the patient is not currently being treated with metformin: The initial dose of this drug is a total daily dose of linagliptin 5 mg and metformin hydrochloride 1000 mg; the dose of metformin hydrochloride may be gradually increased up to the maximum recommended daily dose of 2000 mg. 2. If the patient is being treated with metformin - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the initial dose of this drug is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride. - For patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea or metformin and insulin, the initial dose of this drug should be considered as a total daily dose of linagliptin 5mg and a dose of metformin hydrochloride similar to the patient's current dose. When this drug is administered concomitantly with insulin or a sulfonylurea, a reduction in the dose of insulin or the sulfonylurea may be necessary to reduce the risk of hypoglycemia. - When switching from an immediate-release metformin formulation to an extended-release formulation, glycemic control should be closely monitored, and dosage adjustments should be made as appropriate if necessary. - When switching from combination therapy with linagliptin and extended-release metformin to this drug, the dose of this drug should be the current doses of linagliptin and extended-release metformin hydrochloride. Because dosage adjustment according to renal function is necessary, assessment of renal function is recommended before and periodically after administration of this drug. No dosage adjustment of this drug is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73m2]. In patients with moderate renal impairment (CKD stage 3A), with creatinine clearance (CrCl) of 45mL/min or more and less than 60mL/min, or estimated glomerular filtration rate (eGFR) of 45mL/min/1.73m2 or more and less than 60mL/min/1.73m2, this drug may be used with adjustment of the metformin hydrochloride dose as follows, provided it is well tolerated and the patient has no other conditions that may increase the risk of lactic acidosis. The starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily; therefore, treatment should not be initiated with this drug. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to less than 45mL/min or estimated glomerular filtration rate (eGFR) decreases to less than 45mL/min/1.73m2, this drug must be discontinued immediately.

Ingredients

Manufacturer
Daewon Biotech Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication is used alongside dietary and exercise therapy to help improve blood sugar control in patients with type 2 diabetes. Linagliptin and Metformin work together to effectively lower blood sugar levels. In other words, this medication is used as an adjunct for patients with difficulty managing their blood sugar.

How to take

Adult dose

In antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5 mg and metformin hydrochloride extended-release 2000 mg. This drug should be taken once daily with a meal, preferably with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. To maintain the extended-release properties, swallow this drug whole; do not split, crush, grind, or chew it. Take 1 tablet of this drug 5/1000 mg extended-release tablet once daily. Patients taking this drug 2.5/750 mg extended-release tablet or 2.5/1000 mg extended-release tablet should take 2 tablets together once daily. 1. If the patient is not currently being treated with metformin: The initial dose of this drug is a total daily dose of linagliptin 5 mg and metformin hydrochloride 1000 mg; the dose of metformin hydrochloride may be gradually increased up to the maximum recommended daily dose of 2000 mg. 2. If the patient is being treated with metformin - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the initial dose of this drug is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride. - For patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea or metformin and insulin, the initial dose of this drug should be considered as a total daily dose of linagliptin 5mg and a dose of metformin hydrochloride similar to the patient's current dose. When this drug is administered concomitantly with insulin or a sulfonylurea, a reduction in the dose of insulin or the sulfonylurea may be necessary to reduce the risk of hypoglycemia. - When switching from an immediate-release metformin formulation to an extended-release formulation, glycemic control should be closely monitored, and dosage adjustments should be made as appropriate if necessary. - When switching from combination therapy with linagliptin and extended-release metformin to this drug, the dose of this drug should be the current doses of linagliptin and extended-release metformin hydrochloride. Because dosage adjustment according to renal function is necessary, assessment of renal function is recommended before and periodically after administration of this drug. No dosage adjustment of this drug is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73m2]. In patients with moderate renal impairment (CKD stage 3A), with creatinine clearance (CrCl) of 45mL/min or more and less than 60mL/min, or estimated glomerular filtration rate (eGFR) of 45mL/min/1.73m2 or more and less than 60mL/min/1.73m2, this drug may be used with adjustment of the metformin hydrochloride dose as follows, provided it is well tolerated and the patient has no other conditions that may increase the risk of lactic acidosis. The starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily; therefore, treatment should not be initiated with this drug. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to less than 45mL/min or estimated glomerular filtration rate (eGFR) decreases to less than 45mL/min/1.73m2, this drug must be discontinued immediately.

Precautions

This medication can rarely cause a serious condition known as lactic acidosis, which can lead to death, so it must be used with extreme caution. Patients with allergies to the active ingredients or excipients, type 1 diabetes, lactic acidosis, diabetic ketoacidosis, severe renal impairment, or serious liver dysfunction should not take this medication. Additionally, it should not be used during acute diseases that can affect renal function, such as dehydration, severe infection, acute myocardial infarction, or shock. This medication may cause hypoglycemia, so when taken with insulin or sulfonylureas, blood sugar should be monitored closely and dosages adjusted as necessary. To reduce the risk of lactic acidosis, renal function should be routinely checked, and elderly patients or those with signs of dehydration should take extra caution. Skin conditions such as acute pancreatitis or bullous pemphigoid may occur, so if severe abdominal pain or skin abnormalities develop during use, contact a doctor immediately. This medication may lower vitamin B12 levels, so regular checks for vitamin B12 deficiency are advisable during prolonged use. Do not crush, chew, or break the tablet; swallow it whole, even if the tablet shell appears in the stool, as this is a normal occurrence. This medication may interact with other drugs; therefore, inform healthcare professionals of any other medications being taken, especially those that can affect kidney function. During pregnancy or breastfeeding, it is advisable to avoid this medication; if planning to become pregnant, consult with healthcare professionals to determine appropriate treatment options. Elderly patients often have decreased kidney function, so renal function should be checked frequently when using this medication, and dosages should be adjusted to the minimum necessary. Overdose may cause gastrointestinal disturbances or lactic acidosis, so strictly adhere to dosing guidelines and seek immediate medical attention for any abnormal symptoms. Finally, keep this medication out of the reach of children, store in a cool, dry place, and do not transfer it to another container.

Side effects

Severe lactic acidosis, hypoglycemia, angioedema, urticaria, lactic acidosis, abnormal vitamin B12 absorption test, hypoglycemic episode, taste disorder, cough, decreased appetite, diarrhea, constipation, nausea, pancreatitis, vomiting, abdominal pain, oral ulcer, abnormal liver function test, hepatitis, pruritus, erythema, rash, pemphigoid, severe and debilitating arthralgia, rhabdomyolysis, increased lipase, increased amylase, nasopharyngitis, hypersensitivity reaction, constipation, upper abdominal pain, enterocolitis, intestinal obstruction, gastroenteritis, herpes zoster, cystitis, acute pyelonephritis, bronchitis, vestibular neuronitis, sepsis, pneumonia, decreased appetite, dehydration, hyperglycemia, cerebral infarction, stuttering, Alzheimer's-type dementia, chest pain, fever, facial edema, fatigue, chronic obstructive pulmonary disease, asthma, diabetic foot disease, skin lesions, liver metastasis, acute leukemia, basal cell carcinoma, non-small cell lung cancer, malignant pericardial effusion, stomach cancer, rectal cancer, pancreatic cancer, meniscus injury, pneumoconiosis, congestive heart failure, angina pectoris, acute myocardial infarction, unstable angina, cardiac arrest, diabetic retinopathy, acute kidney injury, end-stage renal disease, acute cholangitis, acute cholecystitis, cholangitis, dizziness, kidney transplant failure, anxiety, mood disorder, insomnia, depression, contusion, bone contusion, concussion, bone fracture, hand fracture, laceration, palpitations, dry eye, glaucoma, cataract, ocular discomfort, allergic conjunctivitis, polyuria, proteinuria, stress urinary incontinence, hematuria, hypotension, flushing, hepatic steatosis, cholelithiasis, hearing loss, erectile dysfunction, goiter, anemia, nausea, gastroesophageal reflux disease, dizziness, sensory loss, chest discomfort, weakness, epistaxis, oropharyngeal pain, voice disorder, allergic rhinitis, exercise-induced dyspnea, wet cough, rhinorrhea, pulmonary mass, arthralgia, osteoporosis, arthropathy, musculoskeletal discomfort, myositis, myalgia, soft tissue mass, postmenopausal osteoporosis, rotator cuff syndrome, increased triglycerides in the blood, decreased hemoglobin, increased potassium in the blood, increased creatinine in the blood, increased creatine kinase levels in the blood, increased ALT, hypertension, male-pattern hair loss, hyperhidrosis, dermatitis, anxiety, confusion, nocturia, dermatitis

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication tightly closed in a container to protect it from air and moisture. The storage temperature should be maintained between 1 to 30 degrees Celsius at room temperature.

Appearance and packaging

Appearance

Light pink, convex on both sides, oval-shaped extended-release film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.